Altamira Therapeutics LTD. (CYTOF) SEC Filings — 2024

Filings

• Altamira Therapeutics Files December 2024 6-K Report — 6-K · Dec 20, 2024
• Altamira Therapeutics LTD. SC 13G Filing — SC 13G · Nov 14, 2024
• Altamira Therapeutics Faces Nasdaq Delisting Risk — 6-K · Oct 4, 2024
• Altamira Therapeutics Ltd. Files 6-K Report — 6-K · Sep 24, 2024
• Altamira Therapeutics Launches Public Offering — 6-K · Sep 19, 2024
• Altamira Therapeutics Files 20-F/A Amendment — 20-F/A · Jul 1, 2024
• Altamira Therapeutics Files May 2024 6-K Report — 6-K · May 16, 2024
• Altamira Therapeutics Ltd. Files Amendment to Annual Report — 20-F/A · Apr 22, 2024
• Altamira Therapeutics Files Routine 6-K Report — 6-K · Apr 16, 2024
• Altamira Therapeutics Ltd. Files Annual Report on Form 20-F — 20-F · Apr 10, 2024
• Meyer Amends Altamira Therapeutics Filing — SC 13D/A · Mar 13, 2024
• Altamira Files Pro Forma Financials for Bentrio® Spin-Off — 6-K · Jan 19, 2024